Precise infliximab exposure and pharmacodynamic control to achieve deep remission in pediatric crohn's disease

Active Project Grant Awarded Last action

Award ID
R01DK132408
Recipient
Awarding agency
Obligated
$4,811,170

Award facts

Completion date 91% complete
Place of performance
Cincinnati, OH 45229, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Crohn's disease is a chronic illness that results in intestinal inflammation and unwanted gastrointestinal symptoms. The only biologic (monoclonal antibody) approved for moderate to severe crohn's disease in children (

Transactions

Action Obligated Date
Amendment $655,158
Amendment $662,152
Amendment $642,469
Amendment $642,469
Amendment $709,626
Amendment $709,626
Original award $789,670

Subawards

Subrecipient Amount Awarded
Cleveland Clinic Lerner College Of Medicine Of Case Western Reserve University Precise Infliximab Exposure and Pharmacodynamic Control to Achieve Deep Remission in Pediatric Crohn's Disease $27,001
Children's Specialty Group, PLLC $40,817
University Of California, San Diego $43,880
Cleveland Clinic Lerner College Of Medicine Of Case Western Reserve University $27,811
The Leland Stanford Junior University $117,742
Research Institute At Nationwide Children's Hospital $82,587
The Nemours Foundation $24,991
Trustees Of Indiana University $98,679

Quick answers

Who received award R01DK132408?

R01DK132408 was awarded to Childrens Hospital Medical Center by National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes of Health) on June 1, 2022.

How much is award R01DK132408 worth?

$4,811,170 has been obligated on R01DK132408.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login